Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Primary Open Angle Glaucoma (POAG)
A subtype of glaucomas known as primary open angle glaucoma (POAG) is characterized by an open, seemingly normal anterior chamber angle and elevated intraocular pressure (IOP), with no additional underlying disease. Secondary glaucoma is a condition where the elevated IOP…
What is Photophobia and How to Manage it
Photophobia, or sensitivity to light, is a common condition characterized by discomfort or pain in response to exposure to light. While it can occur in individuals with healthy eyes, photophobia is often associated with underlying eye conditions or systemic diseases.…
Harrow Starts Triesence Relaunch Strategy
Harrow Pharmaceuticals announced its efforts to relaunch Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL in the United States market. The company announced the successful manufacture of the first of three commercial-scale Process Performance Qualification (PPQ) batches required for the relaunch.…
Opus Secures $1.7M Funding from Foundation Fighting Blindness
Opus Genetics, a pioneering gene therapy company focused on inherited retinal diseases, has secured $1.7 million in project-based funding from the Foundation Fighting Blindness. This financial support aims to accelerate the development of two preclinical candidate programs critical for advancing…
FDA Grants Breakthrough and RMAT Status to Aurion’s AURN001
Aurion Biotech has been granted Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) Designation by the FDA for AURN001, Aurion’s innovative allogeneic cell therapy candidate designed to treat corneal edema secondary to corneal endothelial disease. Expediting Development and…
RevOpsis and Kemwell Form Manufacturing Partnership for nAMD
RevOpsis Therapeutics and Kemwell Biopharma have forged a strategic manufacturing partnership aimed at accelerating the development of RO-104, a pioneering tri-specific biologic designed by RevOpsis for treating neovascular age-related macular degeneration (nAMD). Neovascular age-related macular degeneration (nAMD) is a progressive…
Study Identifies Risk Factors for Hydroxychloroquine Retinopathy
A recent study published online in JAMA Network Open sheds light on factors associated with an increased risk for hydroxychloroquine retinopathy. The research, led by April M. Jorge, M.D., from Massachusetts General Hospital in Boston, identifies crucial risk factors beyond…
What is X-Linked Retinitis Pigmentosa
Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time. In about 10% of RP cases, the non-working gene is passed down from the mother…
Metformin Found Ineffective Against Geographic Atrophy
In the quest to find effective treatments for eye diseases, the METformin for the MINimization of Geographic Atrophy Progression (METforMIN) trial sought to evaluate the efficacy of oral metformin in slowing the progression of geographic atrophy (GA) and its effects…
Nordic Pharma Introduces Lacrifill Canalicular Gel for Dry Eye
Nordic Pharma announced the commercial launch of Lacrifill Canalicular Gel, aimed at addressing dry eye disease in the United States. This novel therapy, Lacrifill, is a cross-linked hyaluronic acid derivative that has received clearance from the FDA. Its primary function…